Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06

Key Points

• Adaptive Biotechnologies beat Q3 expectations, reporting EPS of $0.02 versus a forecast loss of $0.10 and revenue of $83.9 million versus $71.6 million expected; management said total-company profitability arrived ahead of schedule.
• Core MRD revenue grew 44%, and the company raised its 2026 MRD revenue outlook to $276 million–$286 million.
• Analysts’ average rating is “Moderate Buy,” with an average 12-month price target of $30.06. Despite the quarterly beat, revenue fell 10.7% year over year and the company remained unprofitable on a net-margin basis.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $30.06.

A number of equities analysts recently issued reports on the stock. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, October 13th. Morgan Stanley raised their target price on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an "equal weight" rating in a research report on Monday, October 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Thursday, October 15th. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Finally, BTIG Research upped their price target on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a "buy" rating in a report on Tuesday, September 22nd.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 11,881 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $25.47, for a total transaction of $302,609.07. Following the sale, the chief operating officer owned 377,802 shares in the company, valued at $9,622,616.94. The trade was a 3.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,050,763 shares of company stock worth $26,806,633. Company insiders own 5.70% of the company's stock.

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently made changes to their positions in the company. Nykredit A S acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth about $31,000. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $35,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $46,000. KBC Group NV acquired a new stake in shares of Adaptive Biotechnologies in the first quarter valued at about $45,000. Finally, Assetmark Inc. increased its stake in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company's stock valued at $61,000 after buying an additional 1,401 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported Q3 earnings of $0.02 per share, versus the consensus estimate of a $0.10 loss, and revenue of $83.9 million, above the $71.6 million expected. Management also said the company reached total-company profitability ahead of expectations. Quarterly results
• Positive Sentiment: Core MRD revenue grew 44%, and Adaptive raised its 2026 MRD revenue outlook to $276 million–$286 million. The company also outlined a target average selling price of $1,700–$1,800, signaling confidence in continued growth of this business. MRD outlook
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 plan and retained a substantial stake. The planned nature of the sales may make them less informative about her outlook, though insider selling can draw investor attention. Insider sale report
• Negative Sentiment: Despite the quarterly beat, revenue was down 10.7% from a year earlier, and the company continued to report a negative net margin. Investors may look for sustained growth and profitability beyond this quarter. Earnings results

Adaptive Biotechnologies Stock Up 0.4%

Shares of NASDAQ ADPT opened at $26.83 on Friday. The company has a market cap of $4.28 billion, a price-to-earnings ratio of -59.62 and a beta of 2.18. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies has a 12 month low of $12.00 and a 12 month high of $30.74. The stock has a 50-day moving average price of $26.39 and a two-hundred day moving average price of $19.81.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.12. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $71.57 million. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.47%. The firm's quarterly revenue was down 10.7% compared to the same quarter last year. During the same period last year, the company posted $0.06 EPS. As a group, analysts forecast that Adaptive Biotechnologies will post -0.40 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation NASDAQ: ADPT is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive's products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.